Peritoneal Microbiome in End-Stage Renal Disease Patients and the Impact of Peritoneal Dialysis Therapy

Area of Science:

• Microbiology
• Nephrology
• Human Microbiome Research

Background:

• Peritoneal dialysis (PD)-related infections remain a significant clinical challenge.
• Emerging research highlights the role of microbiomes in previously sterile body sites.
• Understanding the peritoneal microbiome is crucial for managing infections in end-stage kidney disease (ESKD) patients.

Purpose of the Study:

• To characterize the peritoneal microbiome in ESKD patients without PD therapy.
• To investigate alterations in the peritoneal microbiome of ESKD patients undergoing PD therapy.
• To explore the potential impact of PD on the peritoneal microbiome and infection risk.

Main Methods:

• Cross-sectional study analyzing peritoneal tissue microbiomes.
• 16S rRNA sequencing approach used for microbial analysis.
• Comparison between ESKD patients not on PD (n=11) and those on PD (n=9).

Main Results:

• The peritoneal microbiome in ESKD patients is low-abundance, dominated by Proteobacteria, Firmicutes, Actinobacteria, and Bacteroidetes.
• PD therapy was associated with reduced species richness in the peritoneal microbiome.
• Pseudomonadaceae and Prevotelaceae families were dominant in PD patients.

Conclusions:

• This study presents the first characterization of the peritoneal microbiome in ESKD patients.
• PD therapy may induce significant alterations in the peritoneal microbiome composition.
• Further research is needed to elucidate the clinical relevance of these microbiome changes in PD-related infections.